期刊文献+

神经退行性疾病、胃肠动力异常和肠道菌群失调相互关系的研究进展 被引量:11

Research progress in relationships between intestinal flora imbalance and gastrointestinal motility disorders in neurodegenerative diseases
下载PDF
导出
摘要 阿尔茨海默病(AD)、帕金森病(PD)和多发性硬化症(MS)是常见的神经退行性疾病,往往伴随胃肠道动力异常和肠道菌群失调。肠道菌群已被证明通过神经内分泌系统以及神经免疫系统调控大脑功能,进而影响神经退行性疾病的发生发展。一些神经退行性疾病患者被确诊前就存在胃肠道功能失调,而肠道菌群与胃肠动力异常关系密切,提示肠道菌群也可能通过肠道神经系统影响神经退行性疾病。本文综述了肠道菌群通过神经内分泌-神经免疫互作参与介导胃肠道动力异常的神经退行性疾病的研究进展。 Alzheimer disease,Parkinson disease,and multiple sclerosis are common neurodegen erative diseases,which are often accompanied by gastrointestinal motility disorders and intestinal flora imbalance.Gut microbiota have been shown to regulate brain function through the neuroendocrine system and the nervous immune system.It has been found that gastrointestinal dysfunction occurs earlier than neurodegenerative disease,and that gut microbiota are closely related to gastrointestinal motility.Intes tinal flora may also affect neurodegenerative diseases through intestinal nerve systems.This article aims to review the recent advances in the study of the mechanism by which gut microbiota regulate neurodegenerative diseases with gastrointestinal motility disorders through crosstalk of the neuroendo crine system and the nervous immune system in order to facilitate the future study of the pathophysiology of neurodegenerative diseases as well as the treatment of neurodegenerative diseases from gastroin testine.
作者 杨纯 石海莲 吴晓俊 YANG Chun;SHI Hai-lian;WU Xiao-jun(Shanghai Key Laboratory of Compound Chinese Medicines,the Ministry of Education(MOE)Key Laboratory for Standardization of Chinese Medicines,Institute of Chinese Materia Medica,Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China)
出处 《中国药理学与毒理学杂志》 CAS 北大核心 2019年第7期517-524,共8页 Chinese Journal of Pharmacology and Toxicology
基金 国家自然科学基金(81603354) 国家自然科学基金(81673626) 上海高校特聘教授(东方学者)岗位计划(2013-59) 上海高校中药药效物质E研究院项目~~
关键词 肠道菌群 胃肠动力 神经退行性疾病 肠道菌群-肠-脑轴 gut microbiota gastrointestinal motility neurodegenerative diseases gut microbiotagut-brain-axis
  • 相关文献

参考文献4

二级参考文献35

  • 1田金洲,时晶,魏明清,王永炎.阿尔茨海默病临床诊断标准的中国化[J].中国医学前沿杂志(电子版),2012,4(10):1-7. 被引量:11
  • 2龙子弋,时晶,田金洲,王永炎.痴呆的证候分型研究[J].中国医学前沿杂志(电子版),2012,4(10):28-35. 被引量:31
  • 3Meier JJ, Gallwitz B, Salmen S, et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab, 2003,88: 2719-2725. 被引量:1
  • 4Zander M, Madsbad S, Madsen JL, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallelgroup study. Lancet, 2002,359:824-830. 被引量:1
  • 5Freeman JS. The pathophysiologic role of incretins. J Am Osteopath Assoe, 2007 : 107(Suppl 3): S6-S9. 被引量:1
  • 6Stonehouse A, Okerson T, Kendall D, et al. Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors. Curr Diabetes Rev, 2008,4: 101-109. 被引量:1
  • 7Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exeuatide twice a day for type 2 diabetes: a 26-week randomized, parallel-group, multinational, open-label trial (LEAD-6). Lancet, 2009,374: 39-47. 被引量:1
  • 8Schirra J, Nicolaus M, Woerle HJ, et al. GLP-1 regulates gastroduodenal motility involving cholinergic pathways. Neuro- gastroenterol Motil, 2009,21: 609-618. 被引量:1
  • 9Plutzky J, Garber A, Toft A, et al. Meta-analysis demon-strates that liraglutide, a once-daily human GLP-1 analogue, significantly reduces lipids and other markers of cardiovascular risk in type 2 diabetes. Diabetologia, 2009, 52 (Suppl 1): S299. 被引量:1
  • 10张立苹,田金洲,时晶,林闽,苗迎春,谭中建.轻度认知损害海马结构MR定量与波谱的研究[J].实用放射学杂志,2011,27(6):823-829. 被引量:8

共引文献144

同被引文献178

引证文献11

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部